Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Metastatic Colorectal Cancer-Pipeline Review, H1 2015

Metastatic Colorectal Cancer-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Metastatic Colorectal Cancer-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Metastatic Colorectal Cancer-Pipeline Review, H1 2015', provides an overview of the Metastatic Colorectal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Metastatic Colorectal Cancer Overview 8

Therapeutics Development 9

Metastatic Colorectal Cancer-Therapeutics under Development by Companies 11

Metastatic Colorectal Cancer-Therapeutics under Investigation by Universities/Institutes 18

Metastatic Colorectal Cancer-Pipeline Products Glance 19

Metastatic Colorectal Cancer-Products under Development by Companies 23

Metastatic Colorectal Cancer-Products under Investigation by Universities/Institutes 31

Metastatic Colorectal Cancer-Companies Involved in Therapeutics Development 32

Metastatic Colorectal Cancer-Therapeutics Assessment 104

Drug Profiles 125

Metastatic Colorectal Cancer-Recent Pipeline Updates 386

Metastatic Colorectal Cancer-Dormant Projects 583

Metastatic Colorectal Cancer-Discontinued Products 590

Metastatic Colorectal Cancer-Product Development Milestones 592

Appendix 599

List of Tables

Number of Products under Development for Metastatic Colorectal Cancer, H1 2015 22

Number of Products under Development for Metastatic Colorectal Cancer-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 25

Number of Products under Development by Companies, H1 2015 (Contd..1) 26

Number of Products under Development by Companies, H1 2015 (Contd..2) 27

Number of Products under Development by Companies, H1 2015 (Contd..3) 28

Number of Products under Development by Companies, H1 2015 (Contd..4) 29

Number of Products under Development by Companies, H1 2015 (Contd..5) 30

Number of Products under Investigation by Universities/Institutes, H1 2015 31

Comparative Analysis by Late Stage Development, H1 2015 32

Comparative Analysis by Clinical Stage Development, H1 2015 33

Comparative Analysis by Early Stage Development, H1 2015 34

Comparative Analysis by Unknown Stage Development, H1 2015 35

Products under Development by Companies, H1 2015 36

Products under Development by Companies, H1 2015 (Contd..1) 37

Products under Development by Companies, H1 2015 (Contd..2) 38

Products under Development by Companies, H1 2015 (Contd..3) 39

Products under Development by Companies, H1 2015 (Contd..4) 40

Products under Development by Companies, H1 2015 (Contd..5) 41

Products under Development by Companies, H1 2015 (Contd..6) 42

Products under Development by Companies, H1 2015 (Contd..7) 43

Products under Investigation by Universities/Institutes, H1 2015 44

Metastatic Colorectal Cancer-Pipeline by AB Science, H1 2015 45

Metastatic Colorectal Cancer-Pipeline by AbbVie Inc., H1 2015 46

Metastatic Colorectal Cancer-Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 47

Metastatic Colorectal Cancer-Pipeline by Advenchen Laboratories, LLC, H1 2015 48

Metastatic Colorectal Cancer-Pipeline by Alchemia Limited, H1 2015 49

Metastatic Colorectal Cancer-Pipeline by Allinky Biopharma, H1 2015 50

Metastatic Colorectal Cancer-Pipeline by Amgen Inc., H1 2015 51

Metastatic Colorectal Cancer-Pipeline by Angiogene Pharmaceuticals Limited, H1 2015 52

Metastatic Colorectal Cancer-Pipeline by Array BioPharma Inc., H1 2015 53

Metastatic Colorectal Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 54

Metastatic Colorectal Cancer-Pipeline by AstraZeneca Plc, H1 2015 55

Metastatic Colorectal Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 56

Metastatic Colorectal Cancer-Pipeline by Bavarian Nordic A/S, H1 2015 57

Metastatic Colorectal Cancer-Pipeline by Bayer AG, H1 2015 58

Metastatic Colorectal Cancer-Pipeline by Biocon Limited, H1 2015 59

Metastatic Colorectal Cancer-Pipeline by Biothera, Inc., H1 2015 60

Metastatic Colorectal Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 61

Metastatic Colorectal Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2015 62

Metastatic Colorectal Cancer-Pipeline by Celgene Corporation, H1 2015 63

Metastatic Colorectal Cancer-Pipeline by Celltrion, Inc., H1 2015 64

Metastatic Colorectal Cancer-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 65

Metastatic Colorectal Cancer-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 66

Metastatic Colorectal Cancer-Pipeline by CureTech Ltd., H1 2015 67

Metastatic Colorectal Cancer-Pipeline by DanDrit Biotech A/S, H1 2015 68

Metastatic Colorectal Cancer-Pipeline by Eisai Co., Ltd., H1 2015 69

Metastatic Colorectal Cancer-Pipeline by Eli Lilly and Company, H1 2015 70

Metastatic Colorectal Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 71

Metastatic Colorectal Cancer-Pipeline by Etubics Corporation, H1 2015 72

Metastatic Colorectal Cancer-Pipeline by Exelixis, Inc., H1 2015 73

Metastatic Colorectal Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 74

Metastatic Colorectal Cancer-Pipeline by Genentech, Inc., H1 2015 75

Metastatic Colorectal Cancer-Pipeline by Genor BioPharma Co., Ltd., H1 2015 76

Metastatic Colorectal Cancer-Pipeline by Glycotope GmbH, H1 2015 77

Metastatic Colorectal Cancer-Pipeline by Hospira, Inc., H1 2015 78

Metastatic Colorectal Cancer-Pipeline by Hutchison MediPharma Limited, H1 2015 79

Metastatic Colorectal Cancer-Pipeline by Ignyta, Inc., H1 2015 80

Metastatic Colorectal Cancer-Pipeline by immatics biotechnologies GmbH, H1 2015 81

Metastatic Colorectal Cancer-Pipeline by Immodulon Therapeutics Ltd., H1 2015 82

Metastatic Colorectal Cancer-Pipeline by Immunomedics, Inc., H1 2015 83

Metastatic Colorectal Cancer-Pipeline by Immunovative Therapies, Ltd., H1 2015 84

Metastatic Colorectal Cancer-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 85

Metastatic Colorectal Cancer-Pipeline by Incyte Corporation, H1 2015 86

Metastatic Colorectal Cancer-Pipeline by Kadmon Corporation, LLC, H1 2015 87

Metastatic Colorectal Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 88

Metastatic Colorectal Cancer-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 89

Metastatic Colorectal Cancer-Pipeline by Mabion SA, H1 2015 90

Metastatic Colorectal Cancer-Pipeline by MacroGenics, Inc., H1 2015 91

Metastatic Colorectal Cancer-Pipeline by MedImmune, LLC, H1 2015 92

Metastatic Colorectal Cancer-Pipeline by Merck & Co., Inc., H1 2015 93

Metastatic Colorectal Cancer-Pipeline by Merck KGaA, H1 2015 94

Metastatic Colorectal Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 95

Metastatic Colorectal Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 96

Metastatic Colorectal Cancer-Pipeline by MolMed S.p.A., H1 2015 97

Metastatic Colorectal Cancer-Pipeline by Mologen AG, H1 2015 98

Metastatic Colorectal Cancer-Pipeline by Morphotek, Inc., H1 2015 99

Metastatic Colorectal Cancer-Pipeline by Nektar Therapeutics, H1 2015 100

Metastatic Colorectal Cancer-Pipeline by Nippon Kayaku Co., Ltd., H1 2015 101

Metastatic Colorectal Cancer-Pipeline by Novartis AG, H1 2015 102

Metastatic Colorectal Cancer-Pipeline by Oncobiologics, Inc., H1 2015 103

Metastatic Colorectal Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 104

Metastatic Colorectal Cancer-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 105

Metastatic Colorectal Cancer-Pipeline by Panacea Biotec Limited, H1 2015 106

Metastatic Colorectal Cancer-Pipeline by Pfizer Inc., H1 2015 107

Metastatic Colorectal Cancer-Pipeline by Pharma Mar, S.A., H1 2015 108

Metastatic Colorectal Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 109

Metastatic Colorectal Cancer-Pipeline by Precision Biologics, Inc., H1 2015 110

Metastatic Colorectal Cancer-Pipeline by PsiOxus Therapeutics Limited, H1 2015 111

Metastatic Colorectal Cancer-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 112

Metastatic Colorectal Cancer-Pipeline by Simcere Pharmaceutical Group, H1 2015 113

Metastatic Colorectal Cancer-Pipeline by Symphogen A/S, H1 2015 114

Metastatic Colorectal Cancer-Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 115

Metastatic Colorectal Cancer-Pipeline by TetraLogic Pharmaceuticals, H1 2015 116

Assessment by Monotherapy Products, H1 2015 117

Assessment by Combination Products, H1 2015 118

Number of Products by Stage and Target, H1 2015 120

Number of Products by Stage and Mechanism of Action, H1 2015 129

Number of Products by Stage and Route of Administration, H1 2015 135

Number of Products by Stage and Molecule Type, H1 2015 137

Metastatic Colorectal Cancer Therapeutics-Recent Pipeline Updates, H1 2015 399

Metastatic Colorectal Cancer-Dormant Projects, H1 2015 596

Metastatic Colorectal Cancer-Dormant Projects (Contd..1), H1 2015 597

Metastatic Colorectal Cancer-Dormant Projects (Contd..2), H1 2015 598

Metastatic Colorectal Cancer-Dormant Projects (Contd..3), H1 2015 599

Metastatic Colorectal Cancer-Dormant Projects (Contd..4), H1 2015 600

Metastatic Colorectal Cancer-Dormant Projects (Contd..5), H1 2015 601

Metastatic Colorectal Cancer-Dormant Projects (Contd..6), H1 2015 602

Metastatic Colorectal Cancer-Discontinued Products, H1 2015 603

Metastatic Colorectal Cancer-Discontinued Products (Contd..1), H1 2015 604

List of Figures

Number of Products under Development for Metastatic Colorectal Cancer, H1 2015 22

Number of Products under Development for Metastatic Colorectal Cancer-Comparative Analysis, H1 2015 23

Number of Products under Development by Companies, H1 2015 24

Number of Products under Investigation by Universities/Institutes, H1 2015 31

Comparative Analysis by Late Stage Development, H1 2015 32

Comparative Analysis by Clinical Stage Development, H1 2015 33

Comparative Analysis by Early Stage Products, H1 2015 34

Assessment by Monotherapy Products, H1 2015 117

Assessment by Combination Products, H1 2015 118

Number of Products by Top 10 Targets, H1 2015 119

Number of Products by Stage and Top 10 Targets, H1 2015 119

Number of Products by Top 10 Mechanism of Actions, H1 2015 128

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 128

Number of Products by Top 10 Routes of Administration, H1 2015 134

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 134

Number of Products by Top 10 Molecule Types, H1 2015 136

Number of Products by Stage and Top 10 Molecule Types, H1 2015 136

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

AbbVie Inc.

Actinium Pharmaceuticals, Inc.

Advenchen Laboratories, LLC

Alchemia Limited

Allinky Biopharma

Amgen Inc.

Angiogene Pharmaceuticals Limited

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bavarian Nordic A/S

Bayer AG

Biocon Limited

Biothera, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Celltrion, Inc.

Cellular Biomedicine Group, Inc.

Cornerstone Pharmaceuticals, Inc.

CureTech Ltd.

DanDrit Biotech A/S

Eisai Co., Ltd.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Etubics Corporation

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Genor BioPharma Co., Ltd.

Glycotope GmbH

Hospira, Inc.

Hutchison MediPharma Limited

Ignyta, Inc.

immatics biotechnologies GmbH

Immodulon Therapeutics Ltd.

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Inbiopro Solutions Pvt. Ltd.

Incyte Corporation

Kadmon Corporation, LLC

Karyopharm Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Mabion SA

MacroGenics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Merrimack Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Mologen AG

Morphotek, Inc.

Nektar Therapeutics

Nippon Kayaku Co., Ltd.

Novartis AG

Oncobiologics, Inc.

Oncolytics Biotech Inc.

Otsuka Holdings Co., Ltd.

Panacea Biotec Limited

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Precision Biologics, Inc.

PsiOxus Therapeutics Limited

Regeneron Pharmaceuticals, Inc.

Simcere Pharmaceutical Group

Symphogen A/S

Syndax Pharmaceuticals, Inc.

TetraLogic Pharmaceuticals

Metastatic Colorectal Cancer Therapeutic Products under Development, Key Players in Metastatic Colorectal Cancer Therapeutics, Metastatic Colorectal Cancer Pipeline Overview, Metastatic Colorectal Cancer Pipeline, Metastatic Colorectal Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com